Disclaimer: This information is intended for clinical reference and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made based on individual patient assessment and current clinical judgment.

---

Clinical Malaria

Overview

Definition

Malaria is a mosquito-borne infectious disease caused by parasitic protozoans of the genus Plasmodium. It is characterized by cyclical fevers, chills, anemia, and splenomegaly, ranging from an uncomplicated febrile illness to a severe, life-threatening systemic disease, particularly when caused by Plasmodium falciparum.

Epidemiology

• Global Burden: Estimated 247 million cases and 619,000 deaths worldwide in 2021 (WHO), predominantly in children under 5 years of age.
• Endemicity: Primarily sub-Saharan Africa, South Asia, and parts of Central and South America. High-risk areas are typically tropical and subtropical regions.
• Demographics: The highest mortality rates are observed in young children (under 5), pregnant women, and travelers or non-immune individuals entering endemic areas.

Classification

Five species of Plasmodium cause human malaria:

1. Plasmodium falciparum (P. falciparum): Most common in Africa; responsible for nearly all severe malaria and malaria deaths.
2. Plasmodium vivax (P. vivax): Widely distributed outside Africa, causes recurrent relapses, and can cause severe disease (though less frequently than P. falciparum).
3. Plasmodium ovale (P. ovale): Relatively rare, primarily West Africa; causes relapses.
4. Plasmodium malariae (P. malariae): Globally distributed; causes quartan fever (72-hour cycle) and chronic, low-level infection that can persist for decades.
5. Plasmodium knowlesi (P. knowlesi): Naturally a primate parasite (Southeast Asia); causes quotidian fever (24-hour cycle) and can rapidly progress to severe malaria, similar to P. falciparum.

Type	Cycle Duration	Severity	Relapse Potential
P. falciparum	48 hours (Tertian)	High (Malignant)	No (Recrudescence only)
P. vivax	48 hours (Tertian)	Moderate	High (Hypnozoites)
P. ovale	48 hours (Tertian)	Moderate	High (Hypnozoites)
P. malariae	72 hours (Quartan)	Low/Chronic	Low/Long-term
P. knowlesi	24 hours (Quotidian)	High (Rapid)	No

Pathophysiology

Mechanism

The malaria cycle in humans involves the following key stages:

1. Inoculation: Female Anopheles mosquito injects sporozoites into the bloodstream.
2. Hepatic (Exo-erythrocytic) Stage: Sporozoites rapidly travel to the liver, invade hepatocytes, and multiply asexually into merozoites. In P. vivax and P. ovale, some parasites become dormant hypnozoites, causing relapses weeks to years later.
3. Erythrocytic Stage: Merozoites burst from the liver cells and invade red blood cells (RBCs). They multiply (trophozoites $\rightarrow$ schizonts) until the RBC ruptures, releasing new merozoites and initiating the cyclical fever pattern (paroxysm).
4. Gametocytogenesis: Some parasites differentiate into male and female gametocytes, which are ingested by a feeding mosquito, completing the cycle.

Pathogenesis of Severe Malaria (Primarily P. falciparum): * Cytoadherence: Infected RBCs (iRBCs) express Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) on their surface, causing them to adhere to endothelial cells, particularly in the microvasculature (e.g., brain, lungs, kidneys). This obstructs blood flow (sequestration), leading to local hypoxia, metabolic derangement (lactic acidosis), and end-organ damage (e.g., cerebral malaria). * Hemolysis and Anemia: Massive destruction of infected and uninfected RBCs, leading to severe anemia. * Inflammation: Release of parasitic antigens triggers a systemic inflammatory response (cytokine storm), contributing to fever, shock, and capillary leak.

Risk Factors

• Travel or residence in an endemic area.
• Lack of prior immunity (infants, non-immune travelers).
• Sleeping outdoors without mosquito nets or in accommodation without screens.
• Poverty, lack of access to prophylaxis or treatment.
• Pregnancy (increased susceptibility and risk of severe disease).
• HIV co-infection.

Protective Factors

• Genetic: Hemoglobinopathies (Sickle cell trait Hgb S, Thalassemia), G6PD deficiency, Duffy antigen negativity (protects against P. vivax).
• Behavioral: Insecticide-treated bed nets (ITNs), indoor residual spraying (IRS), mosquito avoidance (clothing, repellents).
• Pharmacological: Chemoprophylaxis and seasonal malaria chemoprevention (SMC).
• Immunity: Repeated exposure leads to partial, non-sterilizing immunity, which reduces the risk of severe disease but not infection (common in adults in endemic areas).

Clinical Presentation

Signs and Symptoms

The classic malaria paroxysm (febrile attack) follows a cold stage, hot stage, and sweating stage, typically lasting 6–10 hours.

Cardinal Features (Uncomplicated Malaria)

• Fever: Cyclical (e.g., 48-hour tertian or 72-hour quartan periodicity), often high-spiking.
• Chills/Rigors: Intense shaking preceding the fever spike.
• Headache
• Myalgia, Arthralgia
• Fatigue
• Nausea, Vomiting, Diarrhea

Early Signs

• Non-specific, flu-like illness (crucial to take a travel history).
• Feeling generally unwell (malaise) before the onset of the characteristic fever cycle.

Advanced Signs (Severe Malaria)

Severity criteria are often defined by WHO guidelines (must have P. falciparum parasitemia plus one or more criteria): * Cerebral Malaria: Unarousable coma (GCS < 11 or Blantyre Coma Score < 3, after correction of hypoglycemia). * Severe Anemia: Hemoglobin (Hb) $< 5$ g/dL (children) or $< 7$ g/dL (adults), with parasitemia $> 10,000/\mu$L. * Renal Impairment: Serum creatinine $> 3$ mg/dL (265 $\mu$mol/L) or oliguria. * Acute Respiratory Distress Syndrome (ARDS): Pulmonary edema, severe breathing difficulty. * Acidosis: Metabolic acidosis (plasma bicarbonate $< 15$ mmol/L or lactate $> 5$ mmol/L). * Hypoglycemia: Blood glucose $< 40$ mg/dL (2.2 mmol/L). * Shock: Systolic BP $< 80$ mmHg (adults) or $< 50$ mmHg (children), cold peripheries, prolonged capillary refill time (often associated with gram-negative co-infection in children). * High Parasitemia: Typically $> 10\%$ (though criteria vary; the absolute percentage must be interpreted in context of host immunity). * Jaundice: Serum bilirubin $> 3$ mg/dL (50 $\mu$mol/L) plus parasitemia.

Atypical Presentations

• Algid Malaria: Presentation primarily with profound circulatory collapse/shock.
• Blackwater Fever: Intravascular hemolysis leading to hemoglobinuria and renal failure (often associated with high parasitemia or quinine misuse).
• Chronic presentation: P. malariae can cause recurrent fevers and nephrotic syndrome (P-malariae-induced quartan malaria nephropathy).
• Fever may be absent, particularly in older children and adults in endemic areas with high immunity.

Physical Examination

Inspection

• General Appearance: Signs of distress, pallor (anemia), jaundice (icterus).
• Coma/Neurological: Assess level of consciousness (GCS, Blantyre score). Look for signs of raised intracranial pressure (rare).
• Circulation: Assessment of capillary refill time, perfusion, and skin color (mottling).
• Urine: Dark urine (hematuria or hemoglobinuria).

Palpation

• Splenomegaly: Enlarged spleen is common, particularly in chronic or recurrent infection. Massive splenomegaly suggests hyperreactive malarial splenomegaly (HMS).
• Hepatomegaly: Enlarged liver possible.
• Abdomen: Tenderness is non-specific.

Special Tests

• Rapid Glucose Check: Essential immediately upon presentation to screen for hypoglycemia (especially in severe malaria and children).
• Neurological Exam: Assess deep tendon reflexes, muscle tone, and fundoscopy (retinal hemorrhages and vessel changes are highly specific signs of cerebral malaria in adults and children).

Diagnostic Approach

History Taking

Key Questions

• Travel History: Did the patient travel to a malaria-endemic area within the last 3-6 months? (Crucial question; symptoms usually appear 7 days to 4 weeks after exposure, but latency can be months/years, especially with P. vivax/ovale).
• Prophylaxis: Was chemoprophylaxis taken? If so, which drug and was adherence perfect? (Lack of prophylaxis significantly increases suspicion.)
• Symptoms: Detailed history of fever pattern (cyclicity?), chills, gastrointestinal symptoms.
• Immune Status: Is the patient a returning traveler (non-immune) or a resident of an endemic area (partially immune)?

Red Flags (Indications for Severe Malaria Assessment/Urgent Intervention)

• Impaired Consciousness (any alteration).
• Respiratory distress/difficulty breathing.
• Inability to tolerate oral fluids (risk of dehydration/hypoglycemia).
• Seizures (more than two in 24 hours).
• Acute oliguria/anuria.
• Profound weakness or inability to stand/walk.

Laboratory Tests

First-Line (Initial Diagnostic Tests)

1. Malaria Blood Smears (Thick and Thin):
   • Thick Smear: Higher sensitivity; used to detect the presence of parasites and quantify the parasite load (parasitemia, typically as parasites per $\mu$L or a percentage of RBCs).
   • Thin Smear: Used for species identification based on morphology (e.g., ring forms, schizonts, gametocytes, Schüffner's dots in P. vivax/ovale).
   • Protocol: MUST be repeated every 12–24 hours for 48–72 hours if initial smears are negative but clinical suspicion remains high (Rule of Three Smears). (P. knowlesi requires rapid diagnosis as it multiplies quickly.)
2. Rapid Diagnostic Tests (RDTs):
   • Detect circulating parasite antigens (Histidine-rich protein 2 [HRP2] for P. falciparum or parasite lactate dehydrogenase [pLDH] for non-falciparum species).
   • High sensitivity, useful for rapid bedside diagnosis, especially in decentralized settings.
   • Limitation: HRP2 tests can remain positive for weeks after successful treatment, and genetic deletions of the HRP2 gene exist. Must be followed by microscopy post-treatment for confirmation of clearance.

Confirmatory (Definitive Diagnostic Tests)

• Polymerase Chain Reaction (PCR): Used primarily in reference laboratories for species confirmation, drug resistance surveillance, or when parasitemia is extremely low, or mixed infections are suspected. Not typically used for acute management in resource-limited settings.

Monitoring

• Complete Blood Count (CBC): Assess for anemia (normocytic, normochromic), thrombocytopenia (classic finding), and leukocytosis/leukopenia (variable).
• Electrolytes, Renal Function (BUN, Creatinine): Monitor for acute kidney injury.
• Liver Function Tests (LFTs): Assessment of bilirubin, transaminases (elevations are common).
• Blood Glucose: Essential for frequent monitoring; hypoglycemia is a major complication, especially with quinine treatment.
• Repeat Parasite Count: Essential for monitoring treatment response (clearance time; typically smears are negative within 2–3 days of effective treatment).

Imaging

Recommended

• Chest X-Ray (CXR): If ARDS or pulmonary edema is suspected (look for bilateral infiltrates).

Advanced

• Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) of the Head: Rarely required, but considered if the cause of coma is unclear, focal neurological signs persist after initiating treatment, or alternative diagnoses (e.g., encephalitis, stroke) are considered. In typical cerebral malaria, the scan is often normal or shows diffuse cerebral swelling.

Management

Acute Management

Immediate (First-Hour Interventions)

1. Assess Severity: Rapidly determine if the patient has severe malaria (WHO criteria).
2. Labs: Obtain blood smears, RDT, blood glucose, and basic chemistry.
3. Initiate Treatment: If severe malaria is suspected or diagnosed, initiate parenteral antimalarial therapy immediately. Do not wait for smear results if clinical suspicion is high and transfer is difficult.
4. Hypoglycemia: Treat immediately with IV dextrose (e.g., 50% dextrose, 0.5–1.0 g/kg in adults; 10% dextrose in children).
5. Seizure Management: Treat with benzodiazepines (e.g., IV or rectal diazepam).

Stabilization (Early Management Priorities)

• Fluid Management: Cautious use of IV fluids; avoid over-resuscitation as this can precipitate pulmonary edema (ARDS). Use isotonic crystalloids (e.g., Normal Saline or Ringer's Lactate) for shock correction (20 mL/kg bolus, reassess).
• Transfusion: For severe anemia (Hb $< 5$ g/dL in children, $< 7$ g/dL in adults), blood transfusion (packed RBCs) is indicated. Transfuse slowly (5-10 mL/kg over 3-4 hours) to avoid fluid overload.
• Intubation/Ventilation: If ARDS or deep coma with compromise of airway protection.

Emergency (Crisis Management)

• Acute Kidney Injury (AKI): If oliguria/anuria persists despite adequate hydration, initiate prompt consultation for potential renal replacement therapy (dialysis).
• Severe Acidosis: Correct underlying causes (e.g., fluid resuscitation, treating shock). Bicarbonate administration is generally not recommended unless acidosis is extreme (pH < 7.0) and renal function is monitored, as it can worsen neurological function.

Chronic Management

Chronic management relates primarily to preventing relapses and managing sequelae.

Pharmacological

• Relapse Prevention: For P. vivax and P. ovale (even in cases initially treated for P. falciparum co-infection):
  • Primaquine: Eliminates hypnozoites in the liver. Requires G6PD testing prior to use, as it can cause life-threatening hemolysis in deficient patients.
    • Dosage (Adults): 0.25 to 0.5 mg/kg daily for 14 days (or 0.75 mg/kg once weekly for 8 weeks).
  • Tafenoquine: Single-dose alternative to primaquine, also requires G6PD testing (used for patients $\geq 16$ years old).

Non-pharmacological

• Rehabilitation: Support for neurological deficits following cerebral malaria.
• Nutritional Support: Correction of possible malnutrition and vitamin deficiencies linked to chronic illness.

Monitoring (Long-term Follow-up)

• Regular checks for splenomegaly (or HMS).
• Follow up neurological and developmental status, especially in children recovering from cerebral malaria.
• Periodic screening for nephrotic syndrome (P. malariae related).

Treatment Algorithms (WHO and CDC Guidelines)

First-Line

1. Severe Malaria (Adults and Children): * Artesunate (IV/IM): Drug of choice globally. Administer until the patient can tolerate oral medication (typically $\geq 24$ hours). * Dosage: 2.4 mg/kg IV or IM at $t=0, 12, 24$ hours, then daily until oral treatment can be completed. * Follow-up: Switch to a full course of an Artemisinin-based Combination Therapy (ACT) once the patient is able to take oral medication (e.g., Artemether-lumefantrine or Dihydroartemisinin-piperaquine).

2. Uncomplicated P. falciparum or Mixed Infection: * Artemisinin-based Combination Therapy (ACT): Standard of care worldwide to protect the artemisinin component and ensure cure. Recommended options vary regionally based on documented resistance: * Artemether-lumefantrine (6 doses over 3 days) * Dihydroartemisinin-piperaquine (once daily for 3 days) * Artesunate plus Amodiaquine or Mefloquine * Note: Quinine is reserved for areas with ACT resistance or when ACTs are unavailable.

3. Uncomplicated P. vivax or P. ovale: * Standard ACT (or chloroquine if sensitive) PLUS a 14-day course of Primaquine (or a single dose of Tafenoquine) for radical cure (hypnozoite elimination) after ensuring G6PD status is safe.

Second-Line

• Quinine: Reserved for ACT failures, lack of ACT availability, or severe malaria where Artesunate is unavailable.
  • Dosage (Adults): 20 mg salt/kg loading dose over 4 hours, followed by 10 mg/kg every 8 hours. Requires continuous cardiac monitoring (risk of QT prolongation, hypoglycemia).
• Clindamycin or Doxycycline: Used in combination with Quinine, usually to complete the 7-day course. These drugs are slow-acting and cannot be used for monotherapy.

Refractory Cases (Treatment Failure/Drug Resistance)

• Confirmed ACT Resistance (Southeast Asia): Prolonged combination therapy using alternative combinations (e.g., combinations including mefloquine, or novel agents).
• Recurrence: Must differentiate between treatment failure (recrudescence), reinfection, or relapse (P. vivax/ovale). Failure requires a change in drug combination.

Complications

Common

• Anemia: Microvascular sequestration and massive hemolysis.
• Thrombocytopenia: Usually resolves spontaneously; rarely causes significant bleeding.
• Dehydration and Electrolyte Imbalance.

Serious (Meet criteria for Severe Malaria)

• Cerebral Malaria: Coma, seizures, long-term neurological sequelae.
• Acute Kidney Injury (AKI): Tubular necrosis, often reversible if treated promptly.
• Acute Respiratory Distress Syndrome (ARDS) / Non-cardiogenic Pulmonary Edema.
• Metabolic Acidosis and Hypoglycemia.
• Disseminated Intravascular Coagulation (DIC): Rare but life-threatening.

Long-term

• Post-Malaria Neurological Syndrome: Rare, characterized by cerebellar ataxia, psychosis, and confusion appearing days to weeks after parasite clearance.
• Cognitive and Behavioral Deficits: Particularly in children surviving cerebral malaria.
• Hyperreactive Malarial Splenomegaly (HMS): Massive splenomegaly, abdominal discomfort, high IgM levels, and possible anemia/cytopenias.

Prognosis

Factors

• Species: P. falciparum and P. knowlesi carry the worst prognosis.
• Immune Status: Non-immune patients (e.g., travelers) have a poorer prognosis for a given level of parasitemia.
• Parasite Load: High parasitemia ($> 10\%$) is associated with very high mortality.
• Complications: The presence of cerebral malaria, ARDS, and shock significantly worsens prognosis. Deep coma and failure to respond to treatment within 24 hours predict poor outcome.

Survival

• Uncomplicated Malaria: Mortality is near zero with prompt, effective treatment.
• Severe Malaria: Mortality remains high, estimated between 10% and 30%, even with optimal intensive care, varying by clinical setting and age (highest in non-immune adults and young children).

Quality of Life

Survivors of cerebral malaria, particularly children, may suffer from lasting neurological impairments (epilepsy, behavioral changes, learning difficulties), significantly impacting long-term quality of life.

Prevention

Primary (Preventing Initial Occurrence)

• Vector Control: Insecticide-treated bed nets (ITNs) are the most effective measure. Indoor residual spraying (IRS).
• Chemoprophylaxis: For travelers and selective populations (e.g., pregnant women in endemic areas). Choice of agent depends on destination resistance patterns:
  • Mefloquine: Weekly, started 2 weeks before travel (risk of neuropsychiatric side effects).
  • Atovaquone/Proguanil (Malarone): Daily, started 1-2 days before travel (well-tolerated, shorter post-travel duration).
  • Doxycycline: Daily, started 1-2 days before travel (risk of photosensitivity, candidiasis).
• Vaccines: RTS,S/AS01 (Mosquirix): WHO-recommended vaccine for children in areas with moderate-to-high P. falciparum transmission, offering moderate protection against severe disease.

Secondary (Early Detection and Intervention)

• Self-testing (RDTs) for fever in endemic areas.
• Prompt access to definitive diagnosis and treatment (within 24 hours of fever onset) to prevent progression to severe disease.

Tertiary (Preventing Complications)

• Appropriate acute management (e.g., careful fluid management to prevent ARDS, early correction of hypoglycemia) to prevent permanent end-organ damage.
• Radical cure for P. vivax/ovale to prevent relapses.

Special Populations

Pediatric

• Severe Malaria: Children often present with severe anemia, hypoglycemia, and profound metabolic acidosis. Coma (cerebral malaria) is common.
• Treatment: Artesunate dosage is 2.4 mg/kg IV/IM, same as adults. Follow-up with ACT based on weight.
• Fluid Management: Extremely conservative; risk of fluid overload is high in severe malaria.
• Hypoglycemia: Monitor rigorously.

Geriatric

• Increased risk of co-morbidities (cardiovascular, renal) complicate fluid and drug management (e.g., risk of cardiotoxicity with quinine).
• Atypical presentations (confusion, weakness without prominent fever) are common.

Pregnancy

• Risk: Pregnant women (especially primigravid) are highly susceptible to severe malaria (including pulmonary edema) and are at high risk of fetal complications (low birth weight, stillbirth).
• Prophylaxis: Continuous preventative treatment (Intermittent Preventive Treatment in Pregnancy, IPTp) with Sulfadoxine-Pyrimethamine (SP) is recommended in endemic areas (starting second trimester). Atovaquone/Proguanil or Mefloquine are generally safe for travel prophylaxis.
• Treatment:
  • First Trimester: Quinine plus clindamycin is the safest treatment, NOT ACTs.
  • Second/Third Trimester: ACTs (Artemether-lumefantrine) are preferred. Severe malaria requires IV Artesunate regardless of trimester.
• G6PD testing required before using primaquine for P. vivax radical cure after delivery, as it is contraindicated during pregnancy.

Comorbidities

• HIV: Higher parasite densities, increased risk of actute and chronic recurrent disease. ACT efficacy may be reduced with certain antiretrovirals (e.g., Efavirenz can induce metabolism of artemisinins).
• Sickle Cell Disease (Trait): Trait confers protection, but clinical malaria in full sickle cell anemia may trigger acute crises.

Clinical Pearls

Diagnostic

• Think Malaria: In any patient with fever and a travel history to an endemic area, malaria is Malaria Until Proven Otherwise (MUTO).
• The Power of Repetition: Never dismiss malaria after a single negative smear; repeat the thick and thin smears every 12–24 hours for three total checks if suspicion is high.
• Recognize P. knowlesi: If a patient from Southeast Asia presents with high parasitemia and rapid progression to severity, suspect P. knowlesi. Treat aggressively like P. falciparum.

Treatment

• Artesunate is King: Use parenteral artesunate for ALL severe malaria cases. It is superior to quinine.
• Hypoglycemia Watch: Monitor blood glucose frequently in all severe cases, and especially in patients receiving quinine.
• ACT Adherence: Treatment requires full adherence to a 3-day course; failure often results from inadequate dosing or premature cessation.

Pitfalls (Common Mistakes to Avoid)

• Ignoring Travel History: Failure to ask about travel or assuming the fever is "just flu."
• Treating Based on RDT Only: RDTs should confirm the presence of P. falciparum antigen, but species identification and quantification require microscopy/smear.
• Overtreating Shock: Over-aggressive IV fluid resuscitation in severe malaria risks pulmonary edema (ARDS).
• Failing to Check G6PD Status: Starting Primaquine or Tafenoquine without G6PD verification can be fatal.

Recent Updates

Guidelines

• WHO Guidelines for Malaria (2022): Strongly reaffirm IV Artesunate as first-line for severe cases. Continued endorsement of ACTs for uncomplicated malaria, tailored to regional resistance.
• Focus on Radical Cure: Increased emphasis on G6PD testing and use of Tafenoquine as a single-dose option for P. vivax radical cure upon availability.

Evidence

• Artemisinin Resistance: Evidence confirms emerging artemisinin partial resistance (delayed parasite clearance) in the Greater Mekong subregion, leading to recommendations for longer treatment courses or non-artemisinin combinations in those areas.

Controversies

• Role of Adjunctive Therapy: Debate continues regarding the routine use of adjunct therapies such as mannitol (for cerebral edema) or steroids (for inflammation). Current evidence does not support the use of corticosteroids or high-volume crystalloids in severe malaria.
• HRP2 Deletions: Growing evidence of P. falciparum parasites losing the HRP2 gene, leading to false-negative RDT results in specific geographic areas (e.g., parts of the Horn of Africa). This mandates increased reliance on microscopy in affected regions.

Key References

Guidelines

• World Health Organization (WHO). Guidelines for Malaria. Latest edition (e.g., 2022).
• Centers for Disease Control and Prevention (CDC). Malaria Guidelines.

Studies

• Dondorp AM, et al. Artesunate versus Quinine in the Treatment of Severe Falciparum Malaria: A Randomized Trial. The Lancet, 2010. (Landmark severe malaria treatment study demonstrating superiority of Artesunate).

Reviews

• White, NJ. Plasmodium falciparum Malaria. New England Journal of Medicine. (Seminal reviews on the pathogenesis and treatment of severe malaria).

---